DSM5 Suggests Opening The Door To Behavioral Addictions

April 23, 2010  |  Posted by Psychiatric Times | No Comments
The recently posted first draft of DSM5 ( has suggested a whole new category of mental disorders called the "Behavioral Addictions". The category would begin life in DSM5 nested alongside the substance addictions and it would start with just one disorder (gambling). None of the other "behavioral addictions" suggested for DSM5 would gain official status as a stand alone diagnosis.

Gone to the Dogs

April 22, 2010  |  Posted by Psychiatric Times | No Comments
Insurance restrictions sometimes make for strange bedfellows. My story begins with a phone call from a man about to lose his job. He said that he had been placed on probation and was about to be fired. He asked if he could see me. We met the following day.

DSM5 Temper Dysregulation—Good Intentions, Bad Solution

April 21, 2010  |  Posted by Psychiatric Times | No Comments
Sometimes you spot a serious problem and figure out a very well-intended solution, only to discover eventually that your solution created as much trouble as the original problem. The workers on DSM5 have spotted an enormously worrying problem—the wild overdiagnosis of childhood bipolar disorder (BD) which has led to a massive increase in the use of antipsychotic and mood stabilizing medications in children and teenagers.

Hallucinations, Self Monitoring—and an Historical Injustice

April 21, 2010  |  Posted by Psychiatric Times | No Comments
I am writing to commend Flavie Waters, MD, for her recent article on auditory hallucinations in psychiatric illness.1 She covers the topic well. Her article is timely and I hope it will contribute to a badly needed reorientation of our field toward the positive symptoms of schizophrenia. However, I am compelled to point out an error of citation that is not the author’s fault.

Can a Banned Psychedelic Drug Really Alleviate PTSD?

April 21, 2010  |  Posted by Psychiatric Times | No Comments
Positive results from a new study on the drug 3,4-methylenedioxymethamphetamine (MDMA)—-also known as ecstasy—-may give new hope to returning war troops with posttraumatic stress disorder (PTSD).